Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

McMaster University

$25,000.00

Development of fixturing and locating device for MRI/TRUS system

FY 2014-15

Summary
Focal Healthcare Inc. is a Toronto-based developer and manufacturer of medical devices, with a vision to shape the nextgeneration of prostate cancer management through technical innovation. Our first products, the Fusion Bx(TM) and FusionTx(TM) systems, will greatly improve the way that prostate cancer is detected, monitored and treated.In North America, 1 in 7 men will be diagnosed with prostate cancer in their lifetime. While incidence rates continue to rise,the existing standard of care is inadequate, and has remained largely unchanged for 25 years. Currently, prostate cancer isdiagnosed through random blind biopsies. However, this method does a poor job discerning the location and extent of thedisease. This often leads to detection/over-treatment of indolent and insignificant cancers, and misdiagnosis/undertreatmentof aggressive and significant cancers. Moreover, as urologists are unsure of disease extent, they generally treatthe prostate as a whole, either surgically removing or irradiating the entire organ. These crude methods are not only oftenineffective, but also adversely affect the lives of the patients. Focal Healthcare Inc. is well positioned to change that.Focal Healthcare Inc.s device combines the benefits of MRI and ultrasound in a process known as Magnetic ResonanceImaging/Trans-Rectal Ultrasound (MRI/TRUS) Fusion. This technology allows specific prostate regions of interest identifiedthrough MR to be accurately targeted during biopsy (Fusion Bx) and therapy (Fusion Tx) procedures. This will improvediagnostic accuracy, enhance therapeutic decision making, and improve clinical outcomes for prostate cancer patients.Through this partnership with the McMaster Manufacturing Research Institute, we will develop our MRI/TRUS Fusiontechnology into the new gold standard tool for prostate cancer care management.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
477714-2014
Name nom
Veldhuis, Stephen
Department département
Mechanical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
1701
Research subject group en
Design and manufacturing
Research subject group fr
Conception et fabrication
Research subject en
Engineering design
Research subject fr
Conception technique
Partie
1
Nb partie
1
Application title
Development of fixturing and locating device for MRI/TRUS system
Keyword
NSERC
Application summary
Focal Healthcare Inc. is a Toronto-based developer and manufacturer of medical devices, with a vision to shape the nextgeneration of prostate cancer management through technical innovation. Our first products, the Fusion Bx(TM) and FusionTx(TM) systems, will greatly improve the way that prostate cancer is detected, monitored and treated.In North America, 1 in 7 men will be diagnosed with prostate cancer in their lifetime. While incidence rates continue to rise,the existing standard of care is inadequate, and has remained largely unchanged for 25 years. Currently, prostate cancer isdiagnosed through random blind biopsies. However, this method does a poor job discerning the location and extent of thedisease. This often leads to detection/over-treatment of indolent and insignificant cancers, and misdiagnosis/undertreatmentof aggressive and significant cancers. Moreover, as urologists are unsure of disease extent, they generally treatthe prostate as a whole, either surgically removing or irradiating the entire organ. These crude methods are not only oftenineffective, but also adversely affect the lives of the patients. Focal Healthcare Inc. is well positioned to change that.Focal Healthcare Inc.s device combines the benefits of MRI and ultrasound in a process known as Magnetic ResonanceImaging/Trans-Rectal Ultrasound (MRI/TRUS) Fusion. This technology allows specific prostate regions of interest identifiedthrough MR to be accurately targeted during biopsy (Fusion Bx) and therapy (Fusion Tx) procedures. This will improvediagnostic accuracy, enhance therapeutic decision making, and improve clinical outcomes for prostate cancer patients.Through this partnership with the McMaster Manufacturing Research Institute, we will develop our MRI/TRUS Fusiontechnology into the new gold standard tool for prostate cancer care management.